Teva Pharmaceutical Industries (TEVJF) Accumulated Expenses (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Accumulated Expenses across 10 years of filings, most recently posting $555.0 million for Q1 2026.

• Quarterly Accumulated Expenses rose 17.09% year-over-year to $555.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $555.0 million (up 17.09% YoY) and the FY2025 annual result came in at $739.0 million, up 18.43% from the prior year.
• Accumulated Expenses fell to $555.0 million in Q1 2026, from $739.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $739.0 million in Q4 2025 and troughed at $432.0 million in Q1 2023.
• A 5-year average of $533.6 million and a median of $496.0 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses dropped 10.63% — and 2025, when it increased 18.43%.
• Tracing TEVJF's Accumulated Expenses over 5 years: stood at $566.0 million in 2022, then rose by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025, then retreated by 24.9% to $555.0 million in 2026.
• Business Quant data shows TEVJF's Accumulated Expenses at $555.0 million in Q1 2026, $739.0 million in Q4 2025, and $561.0 million in Q3 2025.